Clinical trials: Disease Free Survival
Breast Cancer, HER2-positive Breast Cancer
Darsilide Combined With AI, Trastuzumab and Patuzumab in the Neoadjuvant Treatment of HR+/HER2+ Breast Cancer
This study is intended to carry out a single arm, prospective, open clinical study, and use Darsilide combined with endocrine therapy, Trastuzumab and Patuzumab to treat early or locally advanced breast cancer of TPBC before…
- Trial name
- NCT06276868
- Testing
- Dalcilib+letrozole+HP treatment group
- Where
- China
- Volunteers
- 71 people
- Sponsor
- Henan Cancer Hospital
Outcome Assessment, Cancer of Colon
Textbook Outcome in Colon Carcinoma
BACKGROUND: Textbook outcome (TO) is a multidimensional quality management tool that uses a set of traditional surgical measures to reflect an "ideal" surgical result for a particular pathology.
- Trial name
- NCT05675904
- Testing
- Colon oncological resection
- Where
- Spain
- Volunteers
- 564 people
- Sponsor
- Hospital General Universitario de Alicante
Brain Metastases, Adult
A Neurocognitive Study in Patients With Brain Oligometastases Receiving Hypofractionated SRT
Background: For newly-diagnosed patients with brain metastasis, conventional whole-brain radiation therapy (WBRT) might still remain a common palliative management even for those with brain oligometastases.
- Trial name
- HF-SRT (NCT04805255)
- Testing
- Hypofractionated Stereotactic Radiotherapy
- Where
- 2 sites in Taiwan
- Volunteers
- 135 people
- Sponsor
- Chang Gung Memorial Hospital
Colorectal Cancer Metastatic, Liver Metastases
Efficacy of FOLFOX Versus FOLFOX Plus Aflibercept in K-ras Mutant Patients With Resectable Liver Metastases
Patients presenting with multiple innumerable liver metastases will probably never come to resection, however, for all others, including patients with numerous multiple metastases or large metastases, resection should be…
- Conditions
- Colorectal Cancer Metastatic, Liver Metastases, KRAS Mutated Colorectal Cancer
- Trial name
- BOS3 (NCT01646554)
- Testing
- Modified FOLFOX6, Aflibercept, Surgery
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Adenoid Cystic Carcinoma, Sinonasal Carcinoma
SPARE-1st: Surgery Alone vs Surgery Plus Postoperative Radiotherapy for Sinonasal Adenoid Cystic Carcinoma
Background: Sinonasal adenoid cystic carcinoma (ACC) is a rare type of cancer that starts in the nasal cavity or sinuses. Although surgery can remove the tumor, doctors often recommend radiation therapy after surgery to reduce…
- Trial name
- SPARE-1st (NCT07563088)
- Testing
- Postoperative Radiotherapy, Observation
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Eye & ENT Hospital of Fudan University
Critical Limb Ischemia, Peripheral Arterial Disease
Foot Perfusion Analysis to Predict Limb Salvage
This study aims at evaluating the correlation between foot perfusion on angiographies performed before and after revascularization and limb salvage in patients with critical limb ischemia.
- Trial name
- DELTA-PERF (NCT03810469)
- Where
- France
- Volunteers
- 69 people
- Sponsor
- Centre Hospitalier de Valenciennes
Urothelial Carcinoma, Bladder Cancer
Trial of Adjuvant Sutent for Patients With High Risk Urothelial Carcinoma After Neoadjuvant Chemotherapy and Cystectomy
The purpose of this study is to determine whether sutent (sunitinib)is effective in preventing tumor recurrence in patients with high risk bladder cancer who have previously had chemotherapy and cystectomy (bladder removal).
- Trial name
- NCT01042795
- Testing
- Sunitinib
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Michigan
Oligometastatic Disease
Consolidative Radiotherapy Combined With Camrelizumab and Chemotherapy for Oligometastatic Nasopharyngeal Carcinoma
The purpose of this study is to explore the efficacy and tolerance of local consolidative radiotherapy combined with Camrelizumab and chemotherapy in patients with oligometastatic nasopharyngeal carcinoma
- Trial name
- NPC-CR01 (NCT05128201)
- Testing
- consolidative radiotherapy
- Where
- 3 sites in China
- Volunteers
- 63 people
- Sponsor
- Jiangxi Provincial Cancer Hospital
Metastatic Breast Cancer
Patient-reported Outcome Questionnaire for Women With Metastatic Breast Cancer
The goal of the study is to understand the meaning of progression-free survival for women with metastatic breast cancer and to use this understanding to create and distribute a new questionnaire to assess the effect progression…
- Trial name
- NCT01282931
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Health Outcomes Solutions
Locally Advanced Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer
Local Ablative Stereotactic Radiotherapy for Residual Hypermetabolic Lesion in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Long-term Responders to Immunotherapy
At present, it is recommended to continue immunotherapy until progression or unacceptable toxicity. However, only a minority of patients benefits from a durable response and most see the disease progress despite several months of…
- Trial name
- TRAILOCLORI01 (NCT05111197)
- Testing
- SRT, Immunotherapy
- Where
- 5 sites in France
- Volunteers
- 112 people
- Sponsor
- Institut Cancerologie de l'Ouest
Progression-Free-Survival, Recurrence
Clinical Study on Triple Negative Breast Cancer With Chinese Medicine
Breast cancer is one of the most serious threat to women's health of malignant tumors, also the most common causes of cancer death in women.Triple-negative breast cancer (TNBC) refers to the immunohistochemical detection of…
- Conditions
- Progression-Free-Survival, Recurrence, Overall Survival
- Trial name
- NCT03332368
- Testing
- Traditional Chinese medicine
- Where
- 5 sites in China
- Volunteers
- 620 people
- Sponsor
- Sheng Liu
Prostate Cancer
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
This is a prospective study to determine if the adjuvant use of Curcumin improves recurrence-free survival.
- Trial name
- NCT02064673
- Testing
- Curcumin
- Where
- United States
- Volunteers
- 650 people
- Sponsor
- yair lotan
Non-small Cell Lung Cancer
Role of PET Scan in the Evaluation of Early Response to Maintenance Treatment in Advanced Non-small-cell Lung Cancer
Non small cell lung cancer is the first cause of cancer related death in France and is becoming an increasing health problem in developing countries.
- Trial name
- CALMETTE (NCT02507518)
- Testing
- PET scan imaging
- Where
- 5 sites in France
- Volunteers
- 80 people
- Sponsor
- Centre Henri Becquerel
Acute Lymphoblastic Leukemia
Severe Toxicity Free Survival Following Childhood Acute Lymphoblastic Leukemia
The goal of this observational study is to quantify the burden of particularly severe, long-term adverse effects in childhood acute lymphoblastic leukemia (ALL) survivors.
- Trial name
- NCT05639673
- Where
- Denmark
- Volunteers
- 5,000 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Colorectal Cancer, Colorectal Liver Metastases
Adjuvant FOLFIRI Based-chemotherapy After Resection of CLM Responding to Preoperative FOLFIRI
Eligible patients are patients with contraindication to preoperative oxaliplatin based-chemotherapy who underwent resection of no more than 10 colorectal liver metastases after preoperative FOLFIRI based chemotherapy with or…
- Trial name
- IRIMAD (NCT06501482)
- Testing
- Postoperative reintroduction of FOLFIRI based chemotherapy
- Where
- France
- Volunteers
- 254 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Breast Neoplasms
Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells
This phase II trial studies the efficacy of trastuzumab treatment in breast cancer patients with stage II-III human epidermal growth factor receptor 2 (HER2)-negative tumors and HER2-expressing bone marrow disseminated tumor…
- Trial name
- NCT01779050
- Testing
- Doxorubicin, Trastuzumab, Cyclophosphamide
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Washington University School of Medicine
High-Risk Melanoma
Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High-Risk Melanoma
This study will evaluate the immunization effects of a vaccine for patients who are at risk for recurrence of their skin cancer. That is, the risk of cancer is higher if melanoma has invaded deep into the skin or lymph nodes.
- Trial name
- NCT00273910
- Testing
- gp100:209-217 (210M), Montanide ISA-51, Imiquimod
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- National Cancer Institute (NCI)
Non-Muscle-Invasive Bladder Cancer, BCG-Unresponsive Bladder Cancer
Sequential Gemcitabine Plus Docetaxel Versus Gemcitabine Plus Mitomycin C for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer
This prospective, randomized, open-label, phase II clinical trial compares two sequential intravesical chemotherapy regimens in patients with bacillus Calmette-Guérin (BCG)-unresponsive high-grade non-muscle-invasive bladder…
- Trial name
- GEMDOC-MMC (NCT07747740)
- Testing
- Gemcitabin, Docetaxel, Mitomicin C
- Where
- Russia
- Volunteers
- 228 people
- Sponsor
- Blokhin's Russian Cancer Research Center
Esophageal Cancer
Total Intravenous Anesthesia and Recurrence Free Survival
The investigators propose to compare recurrence-free survival in patients having potentially curative (Stages 1-3) surgery for esophageal cancer who will be randomly assigned to propofol-based total intravenous anesthesia or…
- Trial name
- NCT04513808
- Testing
- Propofol-based total intravenous anesthesia, Sevoflurane intravenous anesthesia
- Where
- China
- Volunteers
- 1,614 people
- Sponsor
- The Cleveland Clinic
Non-Hodgkin Lymphomas, Follicular Lymphomas
Bendamustine Plus Rituximab Versus CHOP Plus Rituximab
The study addresses the question if the first line therapy of low malignant and mantle cell lymphomas with bendamustine plus rituximab is comparable (non inferior) with CHOP plus rituximab with regard to progression free survival…
- Conditions
- Non-Hodgkin Lymphomas, Follicular Lymphomas, Immunocytomas, Lymphocytic Lymphomas
- Trial name
- NCT00991211
- Testing
- Bendamustine, Standard chemotherapy CHOP + Ritiximab
- Where
- Germany
- Volunteers
- 549 people
- Sponsor
- University of Giessen